Analysts Raise Amgen Price Targets After Q3 Results
RBC Capital raised its Amgen target to $470 from $430, while Citigroup lifted its target to $465 from $405. Both changes followed Amgen’s higher-than-expected Q3 results and upward revision to full-year guidance.
Following Amgen's third-quarter 2026 earnings announcement, several financial institutions updated their outlooks on the company's stock. RBC Capital adjusted its price target for Amgen to $470 from $430, while Citigroup raised its target to $465 from $405. These adjustments follow the company's report of higher-than-expected quarterly results and an upward revision to its full-year financial guidance.